Researchers behind a major international study aim to unravel the secrets of why a tiny percentage of cancer patients survive longer than others.
The Rosalind study will work with ‘cancer super survivors’ diagnosed with some of the most aggressive forms of the disease in the hope of learning how and why they beat the odds.
Cancer specialists in more than 40 countries are taking part. The study hopes to recruit 1,000 patients who have been diagnosed with small cell lung cancer, as well as specific brain and pancreas cancers.
Only patients in the top 3% in terms of cancer survival will be eligible for the research, which will hunt for differences in their immune systems and study tumour samples for genetic quirks and cancer weaknesses.
